Telix Pharmaceuticals

Telix Pharmaceuticals Intangible Assets

The Intangible Assets of Telix Pharmaceuticals (TLX.AX) as of Nov 20, 2026 is 393.84 M USD. In the previous year, Intangible Assets was 191.27 M USD — a change of 105.90% (higher).

Intangible Assets

393.84 MUSD

YoY

105.90%

Last updated:

Intangible Assets of Telix Pharmaceuticals is 2025 393.84 M USD. Intangible Assets of Telix Pharmaceuticals was 2024 191.27 M USD. It decreases by 105.90% higher compared to the previous year.

The Telix Pharmaceuticals Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
36.31 M USD
Jan 1, 2019
37.72 M USD
Jan 1, 2020
54.97 M USD
Jan 1, 2021
51.63 M USD
Jan 1, 2022
34.67 M USD
Jan 1, 2023
75.05 M USD
Jan 1, 2024
191.27 M USD
Jan 1, 2025
393.84 M USD
The Telix Pharmaceuticals Intangible Assets history
YEARIntangible AssetsYoY
393.84 MUSD+105.90%
191.27 MUSD+154.85%
75.05 MUSD+116.47%
34.67 MUSD-32.85%
51.63 MUSD-6.06%
54.97 MUSD+45.70%
37.72 MUSD+3.89%
36.31 MUSD+2,307.87%
1.51 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

Intangible Assets of Telix Pharmaceuticals is 393.84 M USD in 2025.

Intangible Assets of Telix Pharmaceuticals changed from 191.27 M USD to 393.84 M USD, representing a 105.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Telix Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals